Title
Hyaluronan, neural stem cells and tissue reconstruction after acute ischemic stroke.

Permalink
https://escholarship.org/uc/item/1365447z

Journal
Biomatter, 3(1)

ISSN
2159-2527

Authors
Moshayedi, Pouria
Carmichael, S Thomas

Publication Date
2013

DOI
10.4161/biom.23863

Peer reviewed
Hyaluronan, neural stem cells and tissue reconstruction after acute ischemic stroke

Pouria Moshayedi and S. Thomas Carmichael*

Department of Neurology; David Geffen School of Medicine at UCLA; Los Angeles, CA USA

Keywords: stroke, neural repair, regeneration, hyaluronan, brain

Introduction: Focal Ischemic Stroke

Acute ischemic stroke is one of the main causes of mortality and disability. It annually affects 93 new and recurrent cases per 100,000 population in the US, which imposes a direct economic cost of over $73 billion.1 There is only one approved medical therapy for stroke: tPA is a “clot busting” agent that acts to reperfuse damaged brain, and must be given within 4.5 h of the stroke onset. However, the affected patients are left with lifelong motor, sensory and cognitive disabilities,2 which indicates that despite reperfusion associated with opening of an occluded blood vessel there exists non-salvaged and damaged brain tissues. Therefore neural repair strategies are required to improve neurological dysfunction.

The most common stroke subtype is non-hemorrhagic stroke, caused by a sudden arterial occlusion that disrupts blood flow to brain tissue3 and leads to tissue necrosis in the center of the territory of occluded artery, known as the infarct core.3 Brain areas that are adjacent to the stroke and connected to the region that will become the infarct core survive the stroke. Evidence from human and animal studies indicates that plasticity in the regions of the brain adjacent to and connected with the stroke exhibit the most recovery of function.4-6 Mechanisms of recovery in these areas include neurogenesis, in which newly born immature neurons migrate into the peri-infarct cortex in large numbers and may provide a direct trophic support or cell replacement in this tissue. Also, axons in peri-infarct cortex sprout new connections by activating a specific “sprouting transcriptome.” Recovery is also seen in the remapping of motor and sensory maps in peri-infarct cortex.4-6

However, this recovery is limited, making stroke the leading cause of adult disability. Neuronal circuits in peri-infarct cortex are stunned or dysfunctional, exhibiting increased inhibition7 and altered responses to excitatory signals.8 Experimental studies have shown that the self-repair processes of axonal sprouting and neurogenesis could be enhanced by specific treatment directed at tissue reorganization, as opposed to neuroprotective strategies which maximize the extent of spared neurological functions by protecting the brain tissue against active cell death mechanisms.9 Because neural repair processes occur over weeks and months after the stroke they may be amenable to more delayed treatments that could be given to a wider array of patients than acute neuroprotective therapies.10

Ischemia, among many changes, induces the proliferation and migration of endogenous neural stem and progenitor cells (NSPCs) in the brain.11,12 These play a neuroprotective role by modulating intrinsic inflammatory responses to injury.12,13 Transplanted stem/progenitor cells may enhance these endogenous processes after stroke such as axonal sprouting, neurogenesis and angiogenesis.13,14 Stem/progenitor cells can also directly integrate into damaged neural networks by differentiating into neurons and glial cells,5,16 although this does not appear to be a substantial element in the tissue repair after NSPC transplantation.17 Stem cell transplantation after stroke can both enhance endogenous repair processes and potentially create new neuronal circuits or brain architecture in partially damaged areas next to the stroke core. Therefore, stem cell transplantation is a therapeutic option for post-stroke neural damage.

However, there are pre-clinical and clinical challenges that limit the application of neural stem/progenitor cells in stroke. Peri-infarct tissue is the area where the most significant post-stroke...
regeneration occurs and therefore transplanted cells need to be delivered as close as possible to that area for a maximum effect on the recovering circuits after stroke. However, direct injection of stem/progenitor cells into the peri-infarct cortex carries the theoretical risk of damaging the very tissue that recovers after stroke. The infarct cavity is a compartmentalized area of dead, necrotic core of infarcted tissue does not provide transplanted cells with a viable matrix and required growth factors to help them regenerate and reorganize the damaged tissue. As infarcted or damaged tissue is a target for neural repair in stroke and other CNS degenerative diseases the limited vascular and trophic support and increased inflammation in this target region can be an explanation as to why clinical stem cell therapy had limited success or variable outcome in patients suffering from disorders such as stroke and Parkinson.

A potential solution to stem cell targeting in stroke is the encapsulation of neural stem/progenitor cells in a bio-compatible matrix to enhance their survival and/or differentiation in stroke. Such a matrix might provide signals through the structure of the hydrogel backbone, the incorporation of growth factors or the inclusion of protein motifs that provide pro-survival, pro-growth or pro-differentiation effects. There have been several studies applying biopolymers as carrying scaffolds for neural stem/progenitor cells transplanted to brain focal ischemic lesions (Table 1). In this review, we will focus on the use of Hyaluronan (HA) and discuss options for a bio-compatible hydrogel matrix with a potential to enhance the outcomes of neural cell transplantation for brain ischemic lesions.

Tissue engineering is a multi-faceted approach, as there are several pathologies in damaged tissues that should be corrected. The main deficit in stroke is due to the lost or damaged neuronal circuits. In order to repair injured circuits and possibly restore neurons glial support is needed, as well as a vasculature to supply oxygen and nutrients. Inflammation with both its destructive and constructive roles actively contributes to the brain tissue response to the implanted hydrogel. An efficacious hydrogel design, therefore, should take these into consideration and analyze interactions of the hydrogel elements with the injured brain tissue. We explore in this review the interactions of HA with the processes involved in inflammation, foreign body response, angiogenesis, NPC differentiation and axon growth.

Hyaluronan

HA is a glycosaminoglycan composed of repeated disacharid D-glucuronic acid and N-acetyl-D-glucosamine. It is produced by a membrane-bound group of enzymes named hyaluronan synthases, which organize D-glucuronic acid and N-acetyl-D-glucosamine disacharids into a non-branched linear polymer that can range between 1 MDa to 4 MDa in size; this is what generally known as high molecular weight (HMW) HA. HMW HA is strongly negatively charged and therefore absorbs up to 10–10,000 times its weight water. It is generally a bio-inert molecule that acts to maintain a hydrated and porous environment, absorbs mechanical shock and regulates osmotic balance. HMW HA can also sequester and gradually release growth factors and other bio-active molecules to communicate a local biological influence over cells. HMW HA is specifically interesting from a tissue regeneration perspective.

Table 1. Application of biopolymers in neural stem/progenitor cell therapy of focal brain ischemic lesion

| Article               | Stroke model/species | Cells transplanted/density per animal | Hydrogel                              | Outcomes                                                                 |
|-----------------------|----------------------|--------------------------------------|---------------------------------------|--------------------------------------------------------------------------|
| Bible et al., 2009²    | MCAO/rat             | NSC/3.15 × 10⁶ cells in 30 µl         | Fibronectin-coated PLGA particles     | Descriptive analyses of cell survival, cell-scaffold-tissue integration, cell differentiation, angiogenesis and host inflammatory response |
| Jin et al., 2010³      | MCAO/rat             | hES-NPC/6 × 10⁶ cells in 50 µl        | Matrigel                              | Reduction in lesion volume, improving cell survival, differentiation and behavioral indices |
| Yu et al., 2010⁴       | MCAO/rat             | NSC/1.5 × 10⁶ cells in 5 µl           | Collagen                              | Cell survival, NSC synapse formation and neurological severity score improved |
| Zhong et al., 2010⁴    | PT/mice              | ES-NPC/10⁶ cells in 7 µl              | Hyaluronan /Heparin /Collagen         | Improving transplant cell survival and host inflammatory response, angiogenesis and astrocytic reactivity |
| Matsuse et al., 2011⁵  | MCAO/rat             | MS-NSC/2 × 10⁶ cells, 12 µl in stratum and 8 µl in cortex | Collagen with bFGF in gelatin microspheres | Infarct volume, cell survival and distribution, angiogenesis, number of host NSCs and motor behavior improved |
| Bible et al., 2012⁶    | MCAO/rat             | hNSC/2.1–2.5 × 10⁶ cells in 25–40 µl  | Acellular ECM                         | Descriptive analyses of cell imaging by MRI, cell migration, differentiation and cell-host tissue interaction |

ES, embryonic stem; h, human; MCAO, middle cerebral artery occlusion; MS, mesenchymal stem; NPC, neural precursor cell; NSC, neural stem cell; PLGA, poly(lactic-co-glycolic acid); PT, photothermotic.
engineering standpoint as it can diminish the interaction of encapsulated cells with other cells and growth factors and therefore “conceal” them from local harmful signals; this is mainly done by modulating inflammatory response of macrophages.24 HMW HA can be degraded by enzymes, hyaluronidases, into oligomers that, unlike high molecular HA, are highly bioactive (see below). HA degradation is facilitated in inflammation and injury by the production of reactive oxygen and nitrogen species.25

HA is a reasonable choice to encapsulate cells for transplantation into the brain because it is naturally and abundantly found in the brain.26 HA has a role in the brain more than just space-filling, hydration and matrix provision. HA influences cell adhesion, migration, axon path-finding, brain regional specificity and therefore, it is actively involved in normal development of the brain.26,27 HA is increasingly deposited in the aged brain and diminishes oligodendrocyte precursor (OPC) maturation.28 HA in the demyelinated plaques of multiple sclerosis prohibits OPC maturation and myelin repair.31 HA is a component of the perineuronal net that modulates mature cerebral neurons.29 HA is also involved in brain pathologies and diseases. HA promotes malignant glial cell adhesion, migration and metastasis in the brain.24 It also contributes to mossy fiber sprouting in the hippocampus that will eventually lead to temporal lobe epilepsy.27 HA is involved in immunomodulation, tissue injury and repair in the brain through the innate immune receptors toll-like receptors 2 and 4 (TLR2 and TLR4), signaling through the main inflammatory transcription factor NFκB, and tumor necrosis factor α secretion.26,30 These phenomena are mediated through HA receptors, mainly CD44, RHAMM and TLR4. Hence, HA affects a variety of physiologic and pathologic functions, which makes its application intriguing and challenging.

HA gives different biological signals depending on the molecular weight (see Table 2 for an overview). High molecular HA (> 500 kDa) that is normally found in the brain plays a structural role and silences inflammation, angiogenesis and neural differentiation.32-34 But in pathologies, such as brain ischemic stroke, HA is fragmented into 6- to 40-mers through the action of hyaluronidases and reactive oxygen or nitrogen species. Fragmented HA has a distinct role in activating innate and adaptive immune response, as well as inducing proliferation, motility, and tubule formation of endothelial cells and angiogenesis (refs. 35 and 36 and personal communication with M. Slevin). This effect is mediated by HA receptor CD44 on the endothelial cells.37 This allows tissue engineers to vary the molecular sizes of HA. By encapsulating cells in high molecular weight HA, cells can be transplanted and protected from inflammation upon transplantation in the acute phase of brain damage and through a controlled and gradual degradation, low molecular weight HA is released and can induce angiogenesis and differentiation of stem cell.

Every material implanted in the brain is at risk of being isolated by the brain foreign body response.38 This starts with the brain’s attempt to heal the wound caused by implantation. Upon failure to recognize the implant as “self” or to degrade it, the brain mounts a chronic activation of inflammatory response and gliotic scar formation that will eventually seal-off the “stranger” from accessing normal brain tissue and will effectively cause implant malfunction. From the anti-inflammatory effects of HMW HA it might be predicted that HA will reduce scar formation in the brain and peripheral nerves. This is indeed true:39,40 Figure 2 shows how applying HMW HA can attenuate astrocytic reactivity and scar formation in spinal cord injury. These data render HA gel a bio-compatible choice for neural tissue engineering.

Hyaluronan and Angiogenesis

Nutrients and oxygen can functionally diffuse up to 150–250 μm from blood capillaries.25 The size of infarcted tissue in the brain is several fold larger than this critical range. Therefore any tissue engineering solution for the brain after stroke should consider reconstructing a normal microenvironment with a proper accessibility to oxygen and nutrients, and envisage a solution for the formation of new vessels in tissue constructs. Angiogenesis requires activation of endothelial cells with pro-angiogenic factors (such as vascular endothelial growth factor or VEGF, platelet-derived growth factor or PDGF, fibroblast growth factor or PFG, hepatic
also enhances matrix metalloproteinase (MMP)-2 and -9 expression, promoting matrix degradation and progression of angiogenesis. MMPs also activate endogenous TGF-β that in turn contributes to angiogenesis. Interactions of short chain HA with RHAMM lead to cytoskeletal changes and subsequent migration of endothelial cells that further contribute to the formation of new vessels.26

Growing human umbilical vein endothelial cells (HUVECs) on HA gels improved their proliferation. This augmentation was proportional to the concentration of HA and by using 1% HA gel cells maximally increased their proliferation over 2-fold in a 48 h interval. HA also protects HUVECs against apoptosis induced by serum deprivation. An HA gel enhanced angiogenesis, arteriogenesis and improved ischemia in an experimental model of mice limb ischemia when it encapsulated HUVECs.43 Implanting HA hydrogels in the brain has improved angiogenesis. HA is also important in maintaining vascular integrity. HA has been widely studied and appreciated as a proangiogenic tool in tissue engineering because it can initiate and maintain angiogenesis. HMW HA promotes quiescence in endothelial cells, but oligomeric HA promotes their proliferation and migration; this effect is mediated directly through endothelial cells and also indirectly by inducing inflammatory cells to secrete pro-angiogenic factors. HA relays these messages through CD44, RHAMM and TLR-4 receptors.26,41,42 Long polymers of HA bind to CD44 and interfere with any biological signal transduction; this inhibits endothelial cell proliferation that leads to arrest of angiogenesis. Oligomeric HA, in contrast, attaches to CD44 and promote proliferation of endothelial cells. This molecule also enhances matrix metalloproteinase (MMP)-2 and -9 expression, promoting matrix degradation and progression of angiogenesis. MMPs also activate endogenous TGF-β that in turn contributes to angiogenesis. Interactions of short chain HA with RHAMM lead to cytoskeletal changes and subsequent migration of endothelial cells that further contribute to the formation of new vessels.26

Table 2. A comparative summary of findings in high molecular weight HA vs. low molecular weight HA

| High molecular weight hyaluronan                                      | Low molecular weight hyaluronan                                      |
|-----------------------------------------------------------------------|---------------------------------------------------------------------|
| - Provides hydration and porosity                                     | - Activates immune response                                          |
| - Sequesters and gradually releases bioactive molecules              | - Induces angiogenesis                                               |
| - Conceals encapsulated cells from other cells and humoral factors  | - Promotes proliferation, differentiation and migration of stem/progenitor cells |
| - Keeps stem/progenitor cells in a quiescence state                  |                                                                     |
| - Silences inflammation                                               |                                                                     |
| - Prohibits angiogenesis                                              |                                                                     |
| - Inhibits astrocyte activation and scar formation                   |                                                                     |

Figure 2. Attenuation of astrocyte activation and deposition of chondroitin sulfate proteoglycan (CSPG) by HMW HA gel injection in vivo. Longitudinal images of spinal cord from control (“SCI”) and HA-implanted animals are shown 10 d after spinal cord injury (SCI). Reproduced with permission from reference 39. Scale bar = 100 μm.
Hyaluronan and Neural Stem/Progenitor Cells

There are many indications that HA influences neural stem/progenitor cells in neural tissue development and therefore HA is a suitable candidate to encapsulate NSPCs in neural tissue engineering. HA content is high in developing brain and it declines to 25% two weeks after birth. In vitro studies show that the addition of HA contributes to increasing water absorption and porosity of bio-matrices. Water absorption and resultant changes in the three dimensional HA structure are responsible for some of its biological properties. For example, HA is associated with neural crest cell distribution along the neural tube perhaps by creating a porous milieu for cell migration through the tight cell-cell junction of neuroepithelial cells. Ninety percent of HA is associated with water, suggesting HA contributes to cell migration by providing a loose matrix. HA is diffusely found in the developing brain while NSPCs are migrating in radial or tangential directions. Although HA decreases in postnatal brain, it is still found in cerebellum and corpus callosum, where HA is re-organized into dense meshworks; interestingly, those areas are home to an extensive migration of progenitor cells.

Besides being a permissive conduit for migration, HA actively interacts with cells to tune the cellular machinery for migration. Through RHAMM receptors HA induces calmodulin-mediated signaling that affects actin and microtubule. HA-rich fiber tracts may also function as physical cues guiding the migration of newly born cells in the CNS. It has been suggested that HA induces neural progenitor migration through RHAMM activation, CD44, another known receptor for the HA molecule, is found on NPCs and mediates their interaction with endothelial cells and their transmigration through vessels; these cell functions lead to establishing neurovascular stem cell niche that plays a crucial role in normal adult angiogenesis as well as integration of exogenous transplanted NSPCs.

HA is found in the niche surrounding stem cells and it affects stem cell proliferation and differentiation. It is specifically found in the brain ventricular regions with ongoing stem cell proliferation. HA interaction with CD44 receptor on stem cells influences mitosis spindle formation, which in turn affects symmetric vs. asymmetric division and therefore controls self-renewal vs. differentiation. HA is generally believed to slow the proliferation of stem cells in the brain. Enzymatic HA removal induces proliferation of oligodendrocyte-type 2 astrocyte progenitors, now classified as oligodendrocyte progenitor cells. HA is partly the reason for failed remyelination of demyelinated axons in multiple sclerosis by oligodendrocyte progenitor cells (see Fig. 3 for an illustration): While HMW HA secreted by astrocytes in demyelinated lesions prohibits OPC differentiation to myelin-producing cells, removing HMW HA promotes oligodendrocyte maturation. On the other hand, it has been suggested that degradation of HA promotes proliferation of cells. Moreover, LMW HA (as the degradation product of HMW HA) can induce proliferation, differentiation and migration of NSPCs. Degradation of HA gels encapsulating neural progenitor cells causes differentiation and maturation of those cells; this fits well with the in vivo finding showing a decline in the brain HA content in the postnatal period. It is therefore possible to utilize the dual effect of HA on stem cells by encapsulation of NSPCs in high molecular size HA to prohibit proliferation and maturation, and by a timely degradation of HA and provision of cells with LMW HA turn on their proliferation and differentiation machinery.

These data have inspired researchers to employ HA hydrogel to recapitulate the normal stem cell niche: by providing NSPCs with a 3-dimensional matrix close in composition to the ECM, and by further supplementing HA hydrogel with collagen-1, abundantly found in basal lamina of the subventricular zone. Cells growing in these gels have a lower proliferation rate compared with a 2-dimensional culture, and their neural differentiation improves by almost 5-fold. Other research groups have enriched HA gels with an optimized ratio of collagen or added carefully-tuned amounts of fibroin (produced by Bombyx mori silkworm), heparin sulfate or IKVAV (a protein motif originally found in laminin) plus brain-derived neurotrophic factor to provide NSPCs with an optimally engineered microenvironment to improve their survival, proliferation and differentiation. By altering the hydrogel compliance instead of changing biochemical factors, differentiation of NSPCs to neurons was optimized in gels mimicking neonatal brain compliance vs. those gels similar to adult brain in elasticity. Neural progenitor cells (NPCs) encapsulated in a combined hydrogel made of HA, heparin sulfate and collagen transplanted to the stroke cavity were protected against the host inflammatory insult and their survival improved (Fig. 4). Applying this biopolymer matrix, however, did not influence NPCs differentiation.

Hyaluronan and Axon Growth

Attempts to study the role of HA in axonal local sprouting and long-distance regeneration started with simple histological observations in late 1980s. These found HA as a fine mesh around brain and spinal cord myelinated axons as well as in endoneurial tubes in the peripheral nerves. HA was also found in the perineuronal nets, the specialized ECM structures around cell bodies in the CNS that among many roles also regulate synaptic connectivity.

These phenomenological studies had a clear conclusion: HA is likely to affect a neuron’s physiological functions in the developing and adult nervous system, and also could determine the regenerative response to nervous system injuries. These were the foci for further investigations. HA was found to fine-tune axon pathfinding and contribute to architecturally specific areas in the brain: layer-specific termination of entorhinal fibers to the dentate gyrus, an area responsible for formation of new memories, was abolished by degrading HA molecules. Another region that HA serves as a guidance molecule is the optic chiasm, where those axons of the optic nerve coming from the nasal halves of retina will cross and give rise to the very specific optic pathway. HA localizes in the medial part of the optic chiasm, the point where axon crossing takes place. Data suggests the HA receptor CD44 is involved in mediating the HA role in axon crossing.
Further experiments revealed HA removal deters axon crossing in the optic chiasm. HA is also involved in the nervous system response to injuries and pathological conditions. The presence of HA was correlated with the axon growth in regenerating limbs of larval ambystoma. This finding was echoed in a murine model of peripheral nerve injury: HA was associated with successful axon regeneration and it was co-localized in Schwann cells proliferation areas and the bands of Büngner, two heralds of endogenous peripheral nerve repair. Mossy fiber sprouting in hippocampus is responsible for the formation of a recurrent aberrant excitatory network and the consequent temporal lobe epilepsy. Increases in HA expression in the hippocampus are associated with temporal lobe epilepsy and removing HA in the dentate gyrus protects the brain from epileptogenic chemicals (e.g., kainic acid) that induce mossy fiber sprouting.

These findings prompted researchers to apply HA to promote regeneration in the peripheral and the central nervous systems. Their initial concept considered HA as a hydrated open lattice to allow axon growth as well as free diffusion of nutrients and...
growth factors. Early attempts applied an injectable form of HA to amplify axon growth, myelination and conduction velocity in regenerating peripheral nerve. 67,68 HA also diminished the peripheral scar formation, a known impediment to the regeneration, in re-opposed stamps of peripheral nerves.40

HA promoted regeneration of dorsal root ganglia axons in vitro, but it failed in vivo to induce spinal cord regeneration. 69 These findings revisit the established concept of compromised axon regeneration in the CNS. CNS axons are facing multiple barriers in their internal machinery as well as their surrounding environment in order to mount an effective regenerative response and therefore additional molecules are required to persuade severed axons to re-grow. Hence plain HA gels were supplemented with elements of the ECM or membrane receptor ligands to promote axon growth into the implanted HA matrix in the lesioned brain 70 or spinal cord. 71

**Perspectives and Caveats**

Tissue engineering will fail if it does not address the many pathologies present in the damaged brain tissue. In early stages of neural repair a focus was on neuronal replacement. However, controlling inflammation, securely delivering stem/progenitor cells, promoting angiogenesis, inducing axon regeneration and evading the foreign body reaction are examples of demands from the local environment in a more biologically active tissue repair approach. Further, these are not distinct processes but are inter-related. As discussed in this review, HA is present in the developing and adult brain with a functional consequence for interaction with angiogenesis, inflammation, axonal and cell migration guidance and with effects on cell proliferation and differentiation. This implies applying HA in tissue constructs will modulate inflammation, angiogenesis, stem cell proliferation/differentiation and axon regeneration and therefore improve brain ischemic lesions. In addition to those, tissue engineering capabilities of HA for protein motif incorporation indicate a future in which HA can serve to influence not just the individual elements of tissue repair, but multiple aspects of tissue repair at the same time. However there exists a dual functional role of HA by size (see Table 2) and therefore a successful tissue engineering approach requires an intelligent construction, maintenance and degradation of the HA hydrogel.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Supported by California Institute of Regenerative Medicine grant RT2-01881.

**References**

1. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegel K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:480-6; PMID:19171871; http://dx.doi.org/10.1161/ CIRCULATIONAHA.108.191259.

2. Dobkin BH. Training and exercise to drive post-stroke recovery. Nat Clin Pract Neurol 2008; 4:76-85; PMID:18256679; http://dx.doi.org/10.1038/ncnneu ro0709.

3. Wechsler IR. Intravenous thrombolytic therapy for acute ischemic stroke. N Engl J Med 2011; 364:2138-46; PMID:21931526; http://dx.doi.org/10.1056/ NEJMct1007370.

4. Murphy TH, Corbett D. Plasticity during stroke recovery: from synapse to behavoir. Nat Rev Neurosci 2009; 10:861-72; PMID:19888284; http://dx.doi. org/10.1038/nrn2735.

5. Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol 2006; 59:735-42; PMID:16634041; http://dx.doi.org/10.1002/ana.20845.

6. Brown CE, Aminolrizjari K, Erh H, Winship IR, Murphy TH. In vivo voltage-sensitive dye imaging in adult mice reveals that somatosensory maps lost to stroke are replaced over weeks by new structural and functional circuits with prolonged modes of activation within both the peri-infarct zone and distant sites. J Neurosci 2009; 29:1719-34; PMID:19211879; http://dx.doi.org/10.1523/JNEUROSCI.4249-08.2009.

7. Clarkson AN, Huang BS, Maciasac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 2010; 468:305-9; PMID:21048709; http://dx.doi.org/10.1038/nature09511.

8. Clarkson AN, Overman JJ, Zhong S, Mueller R, Lynch G, Carmichael ST. AMPA receptor-induced local brain-derived neurotrophic factor signaling mediates motor recovery after stroke. J Neurosci 2011; 31:3766-75; PMID:21389231; http://dx.doi.org/10.1523/ JNEUROSCI.5780-10.2011.

9. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4:399-415; PMID:12728267; http://dx.doi.org/10.1038/nrn1106.

10. Carmichael ST. Targets for neural repair therapies after stroke. Stroke 2010; 41(Suppl):S124-6; PMID:20876486; http://dx.doi.org/10.1161/ STROKEAHA.110.597146.

11. Tsai PT, Obah JJ, Kertesz N, Groszer M, Matter C, Gao J, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2010; 30:26329-37; PMID:21173593; http://dx.doi.org/10.1523/JNEUROSCI.5780-10.2011.

12. Bliss TM, Andres RH, Steinberg GK. Optimizing the success of cell transplantation therapy for stroke. Neuronb Dis 2010; 9:240-9; PMID:20791732; http://dx.doi.org/10.1016/j. nbd.2010.02.004.

13. Locatielli F, Bersano A, Ballabio E, Lanfranconi S, Papadimitriou D, Strazzer S, et al. Stem cell therapy in stroke. Cell Mol Life Sci 2009; 66:757-72; PMID:1989624; http://dx.doi.org/10.1007/s00018-008-8346-1.
14. Zhong J, Chan A, Morad L, Krohnblum HI, Fan G, Carmichael ST. Hydrogel matrix to support stem cell survival after brain transplantation in stroke. Neurorehabil Neural Repair 2010; 24:636-44; PMID:20424193; http://dx.doi.org/10.1177/1545968310361958.

15. Blum R, Yassar M, Brown DJ, Durante SM, Touraine J, Pollack BM. Cell transplantation for ischemic brain injury: a critical review. J Comp Neurol 2009; 515:125-44; PMID:19399885; http://dx.doi.org/10.1002/cne.22038.

16. Luo Y. Cell-based therapy for stroke. J Neural Transm 2011; 118:61-74; PMID:20945074; http://dx.doi.org/10.1007/s00702-010-0478-4.

17. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation for stroke. Stroke 2007; 38(Suppl):817-26; PMID:17261476; http://dx.doi.org/10.1161/01.STR.0000247888.25985.62.

18. Mountz JM. Nuclear medicine in the rehabilitative treatment evaluation in stroke recovery. Role of diaschisis resolution and cerebral reorganization. Eur J Med Phys 2007; 43:221-39; PMID:17268887.

19. Lin TN, Sun SW, Cheung WM, Li F, Chang C. Dynamic changes in cerebral blood flow and angiogenesis after transient focal cerebral ischemia in rats. Evaluation with serial magnetic resonance imaging. Stroke 2002; 33:2985-91; PMID:12468801; http://dx.doi.org/10.1161/01.STR.0000065775.98889.DD.

20. Kelly S, Blus TM, Shah AK, Sun GH, Ma M, Fos WC, et al. Transplanted human fetal neural stem cells survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl Acad Sci U S A 2004; 101:18391-4; PMID:15280535; http://dx.doi.org/10.1073/pnas.0404471101.

21. Aurand ER, Lampke KJ, Bigstäd KB. Designing and defining polymers and hydrogels for neural tissue engineering. Neurosci Res 2012; 72:199-213; PMID:22192467; http://dx.doi.org/10.1016/j.neures.2011.12.005.

22. Spicer AP, Tien JY. Hyaluronan and morphogenesis. Birth Defects Res C Embryo Today 2004; 72:199-213; PMID:15054906; http://dx.doi.org/10.1002/bdct.10022.

23. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4:458-39; PMID:15229478; http://dx.doi.org/10.1038/nrc1391.

24. Austin JW, Gilchrist C, Fehlings MG. High molecular weight hyaluronan reduces lipopolysaccharide mediated microglial activation. J Neurochem 2012; In press; PMID:22587438; http://dx.doi.org/10.1111/j.1471-4159.2012.02788.x.

25. Purdue EL, Ibrahim S, Ramamurthi A. Role of hyaluronan in angiogenesis and its utility to angiogenic tissue engineering. Organogenesis 2008; 4:203-14; PMID:19353740; http://dx.doi.org/10.4161/orng.4.6.202.

26. Preston M, Sherman LS. Neural stem cell niches: roles for the hyaluronan-based extracellular matrix. [Schol Ed.] Front Biosci (Schol Ed) 2011; 3:1165-79; PMID:21622263; http://dx.doi.org/10.2741/218.

27. Bausch SB. Potential roles for hyaluronan and CD44 in kiainic acid-induced mossy fiber sprouting in vivo. J Neurochem 2007; 99:787-71; PMID:16577652; http://dx.doi.org/10.1111/j.1471-4159.2006.04778.x.

28. Back SA, Tiabry TM, Chen H, Wallfisndeng F, Craig A, Struve J, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005; 11:966-72; PMID:16086023.

29. Noble PW. Hyaluronan in stromal cell catalyotic products in tissue injury repair. Matrix Biol 2002; 21:259-99; PMID:11827789; http://dx.doi.org/10.1053/j.spmr.2002.050953X1000184.6.

30. Siven M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signalling pathways affecting vascular endothelial cell mitotic and wound healing responses. J Biol Chem 2002; 277:41046-59; PMID:12194965; http://dx.doi.org/10.1074/jbc.M109443200.

31. West DC, Hampson IN, Arnold F, Kumar S. Angiogenesis induced by degradation products of hyaluronic acid. Science 1985; 228:1324-6; PMID:2408340; http://dx.doi.org/10.1126/science.2408340.

32. Al Qeshaita A, Gaffney JJ, Krupinski J, Siven M. Hyaluronan expression following middle cerebral artery occlusion. J Neurosci Res 2007; 85:4131-8; PMID:17111111; http://dx.doi.org/10.1002/jnr.21358.

33. Kidla V, Skandalis SS, Theoharis AD, Theoharis DA, Karmanakos NZ, Papageorgakopoulou N, Giossougianian in cerebrum, cerebellum and brainstem of young sheep brain with particular reference to compositional and structural variations of chondroitin-dermanan sulfate and hyaluronan. Biomol Chromatogr 2008; 22:931-8; PMID:18506744; http://dx.doi.org/10.1002/bmc.1607.

34. Wang YZ, Gao ML, Liu YW, He YQ, Yang CX, Gao F. CD44 mediates oligosaccharides of hyaluronan-induced proliferation, tube formation and signal transduction in endothelial cells. Exp Biol Med (Maywood) 2011; 236:84-90; PMID:21273978; http://dx.doi.org/10.1588/embr.2011.020206.

35. Zhong Y. Bellamkonda VR. Biomaterials for the central nervous system. J R Soc Interface 2008; 5:957-75; PMID:18477539; http://dx.doi.org/10.1098/rsif.2008.0873.

36. Khung ZZ, Milman BD, Vanscoy JE, Seidlits SK, Grill RJ, Schmidt CE. High molecular weight hyaluronic acid limits astrocyte activation and scar formation after spinal cord injury. J Neural Eng 2011; 8:40633; PMID:21752372; http://dx.doi.org/10.1088/1741-2552/8/5/0536.

37. Ozgenel Y. Effects of hyaluronic acid on peripheral nerve scarring and regeneration in rats. Microsurgery 2003; 23:755-81; PMID:14705074; http://dx.doi.org/10.1002/micr.10209.

38. Matou-Naati S, Gaffney J, Kumar S, Siven M. Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signaling pathways involving Cdc2 and gamma-adducin. Int J Oncol 2009; 35:761-73; PMID:19729412.

39. Gao F, Yang CX, Mei W, Liu YW, He YQ. Oligosaccharides of hyaluronan are potential stimulators to angiogenesis via RHAMM mediated signal pathway in wound healing. Clin Invest Med 2008; 31:E106-16; PMID:18544273.

40. Tang ZC, Liao WY, Tang AC, Tsai SJ, Hsieh PC. The enhancement of neural stem cell therapy for angiogenesis in hindlimb ischemia using hyaluronan. Biomaterials 2011; 32:75-86; PMID:20889204; http://dx.doi.org/10.1016/j.biomaterials.2010.08.085.

41. Cui FZ, Tian WM, Hou SP, Xu QI, Lee IS. Hyaluronic acid hydrogel immobilized with RGD peptides for brain tissue engineering. J Mater Sci Mater Med 2006; 17:1393-401; PMID:17143772; http://dx.doi.org/10.1007/s10856-006-0615-7.

42. Lennon FE, Singleton PA. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 2011; 1:200- 13; PMID:22254199.

43. Ibrahim S, Joddar B, Craps M, Ramamurthi A. A surface-tethered model to assess size-specific effects of hyaluronan (HA) on cell spreading. Biomaterials 2007; 28:825-35; PMID:17045332; http://dx.doi.org/10.1016/j.biomaterials.2006.09.930.

44. Collier JH, Camp JP, Hudson TW, Schmidt CE. Synthesis and characterization of polypropylene-hyaluron- 45. Lennon FE, Singleton PA. Hyaluronan regulation of vascular integrity. Am J Cardiovasc Dis 2011; 1:200- 13; PMID:22254199.
59. Seidlits SK, Khaing ZZ, Petersen BR, Nickels JD, Van Scoy JE, Shear JB, et al. The effects of hyaluronic acid hydrogels with tunable mechanical properties on neural progenitor cell differentiation. Biomaterials 2010; 31:3930-40; PMID:20171731; http://dx.doi.org/10.1016/j.biomaterials.2010.01.125.

60. Mescher AL, Cox CA. Hyaluronate accumulation and nerve-dependent growth during regeneration of larval Ambystoma limbs. Differentiation 1988; 38:161-8; PMID:2215934; http://dx.doi.org/10.1111/j.1432-0436.1988.tb0210.x.

61. Bignami A, Asher R. Some observations on the localization of hyaluronic acid in adult, newborn and embryonal rat brain. Int J Dev Neurosci 1992; 10:45-57; PMID:1376955; http://dx.doi.org/10.1016/0736-5748(92)90006-L.

62. Bignami A, Asher R, Perides G. The extracellular matrix of rat spinal cord: a comparative study on the localization of hyaluronic acid, glial hyaluronate-binding protein, and chondroitin sulfate proteoglycan. Exp Neurol 1992; 117:90-3; PMID:1377637; http://dx.doi.org/10.1016/0014-4886(92)90115-7.

63. Tona A, Perides G, Rahemtulla F, Dahl D. Extracellular matrix in regenerating rat sciatic nerve: a comparative study on the localization of laminin, hyaluronic acid, and chondroitin sulfate proteoglycans, including versican. J Histochem Cytochem 1993; 41:593-9; PMID:8450198; http://dx.doi.org/10.1177/41.4.8450198.

64. Förster E, Zhao S, Frotscher M. Hyaluronan-GalNAc receptor antibody and poly-L-lysine to promote axon regrowth after spinal cord injury. J Biomed Mater Res 1998; 41:39-47; PMID:9779641; http://dx.doi.org/10.1002/(SICI)1097-0185(19980118)44:4<394::AID-JBM2>3.0.CO;2-V.

65. Seidlits SK, Khaing ZZ, Petersen RR, Nickels JD, Van Scoy JE, Shear JB, et al. The effects of hyaluronic acid hydrogels with tunable mechanical properties on neural progenitor cell differentiation. Biomaterials 2010; 31:3930-40; PMID:20171731; http://dx.doi.org/10.1016/j.biomaterials.2010.01.125.

66. Chan CK, Wang J, Lin L, Hao Y, Chan SO. Enzymatic removal of hyaluronan affects routing of axons in the mouse optic chiasm. Neuroreport 2007; 18:1533-8; PMID:17885596; http://dx.doi.org/10.1097/WNR.0b013e3282e6065.